Age-related macular degeneration (AMD) is one of the major causes of irreversible blindness among aging populations in developed countries and can be classified as dry or wet according to its progression. Wet AMD, which is characterized by angiogenesis on the choroidal membrane, is uncommonly seen but more severe. Controlling or completely inhibiting the factors that contribute to the progression of events that lead to angiogenesis may be an effective strategy for treating wet AMD. Emerging evidence has shown that transforming growth factor-β (TGF-β) signaling plays a significant role in the progression of wet AMD. In this review, we described the roles of and changes in TGF-β signaling in the development of AMD and discussed the mechanisms of the TGF-β superfamily in choroidal neovascularization (CNV) and wet AMD, including the modulation of angiogenesis-related factors, inflammation, vascular fibrosis, and immune responses, as well as cross-talk with other signaling pathways. These remarkable findings indicate that TGF-β signaling is a potential target for wet AMD treatment.
Introduction
Age-related macular degeneration (AMD) is one of the four major causes of blindness in adults [1] . The pathological changes in the early stage of the disease primarily consist of deposit formation between the retinal pigment epithelium (RPE) layer and Bruch's membrane. Geographic atrophy (GA) at the retina or choroidal neovascularization (CNV) appears during the late stage of AMD [2, 3] . With developing AMD, the patient's central vision is distorted and becomes progressively deficient, eventually resulting in blindness.
Statistical data showed that neovascular AMD, or wet AMD, accounts for 15% of the total number of patients with AMD [4] . Angiogenesis on the choroidal membrane is the major characteristic of wet AMD. Multiple growth factors, such as vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-β), and hypoxia-inducible factor (HIF), play important roles in the formation and progression of CNV and are targets for treating CNV [5] [6] [7] [8] . Currently, anti-VEGF agents, such as ranibizumab and aflibercept, have been used for the treatment of wet AMD and have shown therapeutic benefits. However, a deeper understanding of the mechanisms of CNV has indicated the importance of treatment strategies that target other angiogenic factors in addition to VEGF and inflammatory cytokines [9, 10] . Among these factors, TGF-β may be a potential target for treating AMD [11] .
The TGF-β superfamily is a group of cytokines that play critical roles in embryonic development, immune regulation, inflammatory responses, angiogenesis, and tumorigenesis [12] . In recent years, the role of TGF-β in eye diseases has gradually been revealed. It has been found that TGF-β1 signaling plays an essential role in maintaining the integrity of the blood-retinal barrier [13] . The tight junctions between endothelial cells and astrocytes are required for the formation of the blood-neural barriers (BNB), which include bloodretinal and blood-brain barriers. Therefore, Garcia et al. [13] cocultured ECs and astrocytes to mimic the characteristics of BNB. They found that the activities of endothelial cell γ-glutamyl-transferase (GGT), an indicator of BNB characteristics, were increased by TGF-β, and when anti-TGF-β antibody was added to the medium, GGT activity was decreased. These results suggested that TGF-β is responsible for induction of BNB. Quantification studies also found that activated TGF-β was significantly increased in AMD patients [9] . Tosi et al. [14] investigated the aqueous humor levels of TGF-β and found that they were significantly elevated in AMD patients, even after treatment. In addition, their study suggested that TGF-β1 plays a VEGF-independent role in wet AMD. Moreover, Wang et al. [8] found that TGF-β was highly expressed in laser-induced CNV. Wheeler et al. [15] reviewed the roles of TGF-β signaling in diabetic retinopathy (DR) characterized by retinal neovascularization and suggested that the TGF-β superfamily participates in the proliferation and stabilization of neovascularization at different stages. TGF-β family members influence CNV by regulating VEGF, immunity, vascular fibrosis and other processes [8] . These findings indicated that TGF-β may be a promising target for the treatment of wet AMD. Here, we summarized the complex roles and regulatory mechanisms of the TGF-β superfamily in wet AMD and proposed their potential as therapeutic targets.
Pathophysiology of Age-related Macular Degeneration
AMD refers to the degenerative aging changes in the macula, leading to its loss of function and eventual inactivation [2, 8] . Dry AMD, the most common form of AMD, is characterized by drusens and geographic atrophy that extends to the fovea, whereas wet AMD is marked by CNV and retinal angiomatous proliferation [16] . Although wet AMD is less common, it is the major cause of acute blindness.
CNV is the leading cause of retinal detachment and subretinal hemorrhage and even the loss of central vision due to new blood vessels that penetrate Bruch's membrane [8, 17] . Thus far, the mechanism of CNV is not well understood. Both pro-angiogenic factors and inflammatory cytokines may be involved in the process of CNV. One of the most crucial pro-angiogenic growth factors is VEGF. The up-regulation of VEGF directly promotes the proliferation and migration of endothelial cells. Therefore, neovascularization occurs between the RPE layer and Bruch's membrane. Another possible mechanism is hypoxia. The detachment of the RPE layer and Bruch's membrane due to drusens establishes a hypoxic environment where VEGF is significantly increased, leading to CNV in the subretinal space [17] . Moreover, the accumulation of abnormal extracellular matrix (ECM), inflammation, and the dysfunction of the complement system may lead to the formation of CNV [18, 19] . When CNV is gradually stable for several months or years, it is replaced by a gray-yellow fibrovascular membrane, which later becomes white and eventually forms an atrophy area on the retina and choroid [1] .
TGF-β Signaling Pathway
Angiogenesis is a complicated process that is regulated by multiple factors, including TGF-β, hepatocyte growth factor (HGF), and platelet-derived growth factor (PDGF), in addition to the wellstudied VEGF [20, 21] . Among these factors, the TGF-β superfamily is a group of highly evolutionarily conserved cytokines that are widely distributed in the epithelium, neural tissue and endothelium, and play a context-specific role in regulating cell proliferation, differentiation, apoptosis and immune regulation [22] [23] [24] . More than 40 members are contained in this superfamily and are divided into three subfamilies according to their structure and function: TGF-β, bone morphogenic protein (BMP) and activin [12] .
In mammals, three subtypes of TGF-β, TGF-β1/2/3, were observed. These subtypes are homologous and may be derived from the same ancestral gene [25] . TGF-β1 is the most commonly found TGF-β subtype and is widely involved in various pathophysiological processes, including immune disorders, inflammation, and fibrosis [12, 25] . Conversely, TGF-β2, and TGF-β3 are rarely observed. TGF-β2 plays an important role in cell proliferation and differentiation, embryonic development, bone formation, and development. In addition, some studies have found that TGF-β2 inhibits IL-2-dependent T-cell growth and promotes tumorigenesis [9, 12, [26] [27] [28] . TGF-β3 is more responsible for tissue repair and embryo development.
The extracellular TGF-βs (TGF-β1/2/3) or BMPs (BMP2/4/5/6/7/ 8/9/10) bind to transmembrane TGF-β receptor II (TβRII) or BMP receptor II (BMPRII), respectively, with serine/threonine residues. Upon activation, the phosphate group is transferred to the TGF-β receptor I (TβRI or ALK1-7), initiating intracellular signaling transduction [29, 30] . In the canonical pathway ( Fig. 1) , activated ALKs phosphorylate receptor-regulated Smads (R-Smads, Smad1/5/8 or Smad2/3) and form complexes with common Smad (Co-Smad, Smad4) into the nucleus to regulate DNA transcription. In addition, the non-canonical TGF-β signaling pathway that functions through phosphoinositide 3-kinase (PI3K)-Akt and mitogen-activated protein kinase (MAPK) plays crucial roles in various biological processes including angiogenesis [15] . Geest et al. [31] found that both ALK5 and TβRII were detected in bovine retinal endothelial cells and pericytes. However, the expression level of TβRII was low in bovine retinal pericytes, and ALK1 was only detected in bovine retinal endothelial cells [31] . These findings suggested that the expression condition of various receptors is different in retinal cells.
In addition, the binding of TGF-β ligands to their receptors is modulated by co-receptors, including endoglin and betaglycan, which are also called type III TGF-β receptor (TβRIII). Endoglin is abundant in endothelial cells (ECs) and has been shown to be associated with vascular abnormalities. Recent studies have found that endoglin plays a key role in cardiovascular dysfunction [32, 33] .
Different Roles of TGF-β Signaling in AMD Vasculature
The specific molecular mechanism of TGF-β/BMP signaling in the generation of AMD has yet to be fully elucidated. As mentioned previously, CNV is a characteristic of wet AMD and makes the disease difficult to cure. Many researchers are currently searching for a novel method to inhibit this process. However, angiogenesis or neovascularization is a complicated and multifactorial process that involves many molecules [34] .
Controversial role of TGF-β/BMP signaling in CNV angiogenesis
Various factors including the type and ratio of receptors influence the CNV process. In the vascular system, TGF-βs/BMPs exert both proand anti-angiogenic effects [35] [36] [37] [38] [39] . As shown in Fig. 2 , the pathway activated by ALK5 regulates the transcription of plasminogen activator inhibitor-1 (PAI-1) and other molecules through Smad2/3 and inhibits blood vessel formation. However, when the proportion of ALK1 on the cell surface increases, TGF-β ligand conjugated with endoglin and ALK1 activates the Smad1/5/8 pathway, releasing DNA-binding protein inhibitor (ID-1) and other factors and promoting angiogenesis [40] (Fig. 2) . However, a previous study demonstrated that ALK1 can only play its role in promoting angiogenesis when ALK5 is present [41] . When the ALK5 gene is knocked out, angiogenesis is suppressed, even when the ALK1 ratio is high [41] . This strict regulatory mechanism ensures the reasonable control of blood vessel development.
The effect of TGF-β/BMP signaling in the development of wet AMD is still under debate. Recently, mounting evidence suggests a prominent role for TGF-β signaling in wet AMD, thus advocating a TGF-β-blocking agent for treating wet AMD. Increased aqueous expression of TGF-β1 was found in patients with AMD [14, 28] . In animal models, the expression of TGF-β in the choroid and retinal cells of the experimental group was significantly up-regulated [8] . Furthermore, a group injected with LY2157299, a TGF-β inhibitor, after laser irradiation had less CNV condition [8] . The TGF-β inhibitor peptides P17 and P144 decreased diode laser-induced CNV development and reduced the progression of early CNV lesions in rats [11, 42] . Most recently, Ying et al. [43] demonstrated that the ALK1/2 inhibitor LDN212854 inhibited laser-induced CNV formation. Likewise, Hussein et al. [22] evaluated the levels of BMP2 in the diabetic human retina and found that it had a significant increase in retinal vessels.
Interestingly, Schlecht et al. [44] claimed a different view. They showed that the expression of TGF-β1/2 in the RPE/choroid complex, which stabilized the vascular structure, was 10-fold higher than that in the neural retina [44, 45] . Deletion of TGF-β1/2 in the entire eye or the endothelial-specific deletion of TGF-β signaling caused CNV [44] . In a rat model of AMD, intravitreal injection of TGF-β1 prevented amyloid-β-induced retinal damage [46] . A recent study showed that adenovirus-delivered BMP9 inhibited neovascularization in mouse models using laser-induced CNV [47] . The deletion of TGF-β can induce CNV and increase the permeability of capillaries, leading to microaneurysms and hemorrhage similar to DR [48] . Many studies have confirmed that slightly up-regulated TGF-β promotes EC proliferation; however, at high concentrations, TGF-β exhibited an inhibitory effect due to the altered proportion of TβRI and TβRII on the cell surface [35, 49] .
These discrepancies of TGF-β signaling in AMD may be explained in part by different animal models of AMD, the stage of AMD at the time of treatment, dose, and timing, as well as TGF-β signaling cross-talk with other signaling pathway. However, the above evidence highlighted the importance of the TGF-β signaling pathway in the development of AMD.
Promoting vascular fibrosis in late CNV
Fibrosis is a vital repair mechanism after tissue damage [50] . During the development of CNV, exudation and hemorrhage between RPE cells and choroid cause tissue damage, and at a later stage, fibrosis stabilizes the lesion by generating a fibrous membrane. This process involves RPE cells, glial cells, fibroblasts, and remodeling of the ECM [12, 51] . TGF-β is believed to be involved in fibrotic diseases such as pulmonary fibrosis and liver cirrhosis [24] . Recent studies have shown that TGF-β plays an essential role in the formation of advanced fibrosis in CNV [52] . Zhang et al. [52] successfully induced subretinal fibrosis using an injection of mouse macrophagerich peritoneal cells. They found that the levels of TGF-β1 and TGF-β2 were significantly increased 2 days after fibrosis and peaked on the fifth day by 10-and 20-fold, respectively. After injection of the TGF-β antibody, the degree of fibrosis was remarkably reduced.
In AMD patients, RPE cells can have an epithelial-mesenchymal transition (EMT), which is one of the fibrotic responses that contribute to vision loss. Recently, it was reported that cytokines or growth factors including TGF-β could induce the EMT [53] , but this can only be secondary to the destruction of cell-cell contact. Various mechanisms, including the Smad and Wnt signaling pathways, can be applied to regulate this process [54] . Kimura et al. [53] found that a retinoic acid receptor-γ (RAR-γ) agonist inhibits the EMT of RPE cells, which were mediated by TGF-β, as well as the expressions of EMT markers, such as matrix metalloproteinase (MMP)-2, MMP-3, and others. An in vivo model showed that RAR-γ inhibited the fibrotic reaction of the retina, which was mediated by TGF-β [53] . Moon et al. [55] investigated the effects of bortezomib, a proteasome inhibitor, on the EMT of RPE cells. They found that bortezomib effectively blocks TGF-β1 signaling to inhibit EMT, RPE cell proliferation, and RPE-collagen gel lattices [55] . Therefore, patients with advanced wet AMD who receive TGF-β inhibition therapy may, to some extent, have a delayed occurrence of EMT and subretinal fibrosis and gain more time for the comprehensive application of other treatments.
Mechanisms of TGF-β Signaling on CNV Formation
The molecular mechanism of TGF-β/BMP signaling on wet AMD has been a research hotspot. The multistage features of wet AMD and the diversity of TGF-β functions show that TGF-β/BMP signaling plays different roles at different stages to influence disease progression. Here, we discuss the effects of TGF-β/BMP on wet AMD in terms of the molecular mechanisms, immune regulation, and inflammation.
TGF-β superfamily regulates the expression of angiogenesis-related molecules
Vascular endothelial growth factor TGF-β2 is the isoform that is primarily found in ocular tissue [56] . Bian et al. [57] treated human RPE cells with low dose of TGF-β2 for 24 and 48 h in vitro and found that the secretion of VEGF, an angiogenesis-related protein, was increased by 5-and 9-folds, respectively. The regulation of TGF-β2 on VEGF was fulfilled through the non-canonical pathway. When inhibitors of mitogenactivated protein (MAP), p38, c-Jun N-terminal kinase (JNK), PI3K, and nuclear factor-κB (NF-κB) were used, the secretion of VEGF was significantly decreased [30, 58] . Blaauwgeer et al. [59] cultured human RPE cells in vitro and found that VEGF secretion at the cell base was 4-fold higher than that at the apical region. Moreover, anatomically, the choroid locates next to the RPE, which indicates that TGF-β2 secretion stimulates VEGF release from the RPE to affect choroidal cells and may be critical in AMD pathogenesis. Several studies demonstrated that TGF-β1 induces mRNA Figure 2 . Schematic illustration of the role of TGF-β in angiogenesis The binding between TGF-β and ALK5 activates signal transduction via Smad2/3, which releases PAI-1 and PDGF-B to inhibit EC proliferation and migration, leading to the inhibition of angiogenesis. Meanwhile, activated ALK5/TβRII complexes recruit ALK1 to form heterodimeric complexes with TβRII which functions as an angiogenesis-promoter via the Smad1/5/8 pathway. The ALK1 pathway antagonizes the ALK5 pathway, forming a balance between pro-and anti-angiogenic effects. As a result, the ALK1:ALK5 ratio is a critical way for TGF-β to regulate angiogenesis.
expression of VEGF at the molecular level, resulting in an upregulation of VEGF in RPE cells [58, 60, 61] . However, these in vitro experiments only showed that an increase in TGF-β promoted the expression of VEGF in RPE cells, but did not show that this increase regulated VEGF expression in vivo. For instance, TGF-β1 is thought to be an EC inhibitor that is secreted by regulatory T cells and functions as a suppressor of immune-active cell formation [62] . Thus, TGF-β1 inhibits lymphocyte differentiation and reduces the release of inflammatory factors to avoid tissue damage. In addition, TGF-β1 works through downregulating the levels of VEGF and VEGF receptors (VEGFR) [63] . It is still not clear how these two antagonistic mechanisms affect VEGF expression and angiogenesis in the RPE/ choroid complex and thus more in vivo experiments are required to clarify this issue.
The BMP family can also stimulate angiogenesis by upregulating the expression of VEGF [64, 65] . Hussein et al. [22] found that BMP2 promotes the secretion of VEGF from Müller cells to accelerate the formation of new blood vessels. In addition, growth/ differentiation factor 5 (GDF5) is the first BMP ligand found to play a role in angiogenesis [66] . Yamashita et al. [66] used a chick chorioallantoic membrane and rabbit cornea to examine the functions of GDF5 and BMP2 in angiogenesis. First, they used a chick chorioallantoic membrane assay to explore the roles of GDF5 and other factors in angiogenesis. Their results showed that GDF5 induced new microvessels around the disk. Next, they utilized the rabbit cornea assay to investigate the angiogenesis effects of GDF5. As expected, they found that GDF5 induced the formation of new blood vessels. Notably, the density of new blood vessels was not dependent on the concentration of GDF5, indicating that GDF5 may promote angiogenesis by stimulating fibroblasts to secrete VEGF and ECM [66] .
Connective tissue growth factor
In addition to VEGF, connective tissue growth factor (CTGF/ CCN2) is another important downstream molecule in the TGF-β pathway and plays an important role in fibrosis [67] . As early as 2002, He et al. [68] measured the fibrovascular membrane from mice with advanced AMD and found significantly increased CTGF expression, suggesting that this molecule may aggravate AMD progression. At the same time, when circulating endothelial cells (CEC) cells were treated with CTGF in vitro, their abilities of adhesion, migration, proliferation, and angiogenesis were all enhanced [68] .
Recently, the TGF-β regulation mechanism of CTGF has gradually become clear (Fig. 3) . After TGF-β binds to the receptor, CTGF and its transcription mediator, Src, is activated by the Smad1 pathway. Once CTGF is released from the cell, it forms a complex with integrin β3, activating the Src-Erk1/2 pathway, which enhances Smad1 and results in the positive feedback regulation of CTGF production. In the late stage of CNV, CTGF promotes the proliferation and differentiation of fibroblasts that exist after EMT, up-regulating the production and aggregation of collagen fibers to wrap around the newly-formed vessels and form a stable fibrovascular membrane. It was found that TGF-β-induced collagen mRNA production was significantly reduced after blocking CTGF [51, 69] . Thus, CTGF is known to be an essential mediator of TGF-β in the formation of fibrovascular membranes, making it difficult to cure advanced AMD.
However, recent studies have suggested that CTGF has dosedependent effects; it accelerates fibrosis only at low doses and exhibits inhibitory effects at high doses [51, 70] . The detailed mechanism of this action is still unclear. Gaining a comprehensive understanding of the context-specific role of CTGF should be an important direction for future research. 
TGF-β superfamily alters immune reaction
TGF-β has an immunomodulatory effect and plays an important role in the pathogenesis of ocular disorders. Disruption of the strict regulation of the immunomodulatory effect of TGF-β is a reason for CNV formation [71, 72] . TGF-β secreted by immune and RPE cells plays a critical role in the construction of ocular immune privilege, such as anterior chamber-associated immune deviation (ACAID) [73] . Recent studies showed that TGF-β inhibits not only the proliferation and differentiation of B cells, T cells, NK cells and activated macrophages, but also the secretion of cytokines such as IFN-γ, TNF-α, and IL-2 from Th1 and Th2 cells [74] . Marie et al. [75] demonstrated that the expression of TGF-β1 in RPE cells induced the transformation of naïve CD4
+ cells into regulatory T cells through the FoxP3 pathway. The high level of TGF-β binding on the RPE-Bruch choroidal capillary complex also confirmed the immune privilege in the eye [44, 57, 76] . Under normal conditions, TGF-β promotes the proliferation of fibroblasts and reduces the degradation of the extracellular matrix (ECM) through the canonical pathway by wrapping the abnormal newly-formed blood vessels to mediate tissue repair [57] . However, it is not clear whether TGF-β secreted by peripheral regulatory T cells and transported via the circulation is involved in this process. We predict that when TGF-β declines below a threshold, its inhibitory effect on immune cells will be disrupted, the ACAID effect will be greatly reduced, and the immune reactivity will increase. From this process, the ocular tissue is damaged, including the unregulated secretion of various cytokines such as tumor necrosis factor-α (TNF-α) and IL-6. RPE cells will produce more VEGF, eventually resulting in the proliferation and differentiation of ECs and the development of CNV [44] .
TGF-β superfamily mediates inflammatory reactions
As mentioned previously, inflammation may also promote the formation of CNV. Notably, BMP can also participate in the inflammation process. For instance, a high dose of BMP2 exhibits a stronger effect of the adhering trend of leukocytes to RPE cells. Hussein et al. [22] suggested that BMP2 can stimulate the secretion of cytokines by human retinal endothelial cells (hRECs) such as IL-8, TNF-α (pro-inflammatory), and IL-4 (anti-inflammatory). These cytokines are all active mediators which can cause inflammation and attract leukocytes in the peripheral blood. The levels of pro-inflammatory cytokines were obviously increased with BMP2 treatment. Therefore, as a pro-inflammatory molecule, BMP2 is an excellent accelerator in CNV [22, 76] .
Conclusions and Perspectives
Age-related macular degeneration is a complex disease that involves multiple biological processes and is classified into dry and wet AMD. In particular, choroidal neovascularization is the primary hallmark of the wet form of AMD and leads to vision loss. TGF-β superfamily members have been revealed to participate in the development of AMD, including angiogenesis, inflammatory reactions, immunoregulatory disorders, EC proliferation and migration, and the formation of fibrovascular membranes (Fig. 4) . Different TGF-β family members play different roles in angiogenesis, thus having a balancing function. Recently, mounting evidence suggests a prominent role for TGF-β signaling in wet AMD by regulating the expression of angiogenesis-related molecules, such as VEGF and CTGF, and by mediating immune regulation, inflammation and other pathways. The inhibition or blocking of TGF-β signaling decreases the formation of CNV. However, most studies only revealed the phenomenon, and the underlying mechanisms are still not well understood. Further research should focus on the particular changes in and regulation of TGF-β in various stages of AMD, with the potential to develop alternative therapies for AMD in the future.
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